We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ascitic Fluid Lactoferrin Investigated in Liver Cirrhosis Patients

By LabMedica International staff writers
Posted on 03 Nov 2016
Print article
Image: A histopathology image of hepatocellular carcinoma: the malignant cells seen mostly on the right are well differentiated and interdigitate with normal, larger hepatocytes seen mostly at the left (Photo courtesy of SPL).
Image: A histopathology image of hepatocellular carcinoma: the malignant cells seen mostly on the right are well differentiated and interdigitate with normal, larger hepatocytes seen mostly at the left (Photo courtesy of SPL).
Although elevated levels of lactoferrin provide a biomarker for inflammatory bowel diseases and colorectal cancer, the clinical significance of these elevated levels in ascitic fluid of patients with ascites caused by liver cirrhosis is limited.

The usefulness of ascitic fluid lactoferrin levels for the diagnosis of spontaneous bacterial peritonitis (SBP) in patients with cirrhosis has been investigated and the association between lactoferrin levels and the development of hepatocellular carcinoma (HCC) has been evaluated.

Doctors at the Gyeongsang National University Hospital (Jinju City, South Korea) consecutively enrolled 102 patients with ascites caused by cirrhosis were from December 2008 to December 2011. Liver cirrhosis was defined by the presence of portal hypertension manifested as splenomegaly, varices, ascites, or hepatic encephalopathy, with compatible findings on diagnostic imaging, in combination with thrombocytopenia of less than 100,000/μL). The diagnosis of SBP was based on a polymorphonuclear cells (PMN) count ≥250 cells/mm3 in ascitic fluid, with or without a positive ascitic fluid or blood culture.

Laboratory tests were performed for anti-hepatitis C virus (HCV), hepatitis B virus surface antigen (HBsAg), anti-hepatitis B virus surface antibody (anti-HBs), white blood cell (WBC) count, hemoglobin level, platelet count, prothrombin time- international normalized ratio (PT-INR), total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase, serum albumin, creatinine, CRP, and ascitic fluid analysis, including WBC count, PMN count, and albumin levels.

The lactoferrin level in ascitic fluid was quantified using a human lactoferrin enzyme-linked immunosorbent assay kit (Bethyl Laboratories, Inc., Tokyo, Japan). This kit, designed as a sandwich ELISA, captures human lactoferrin present in samples by anti-lactoferrin antibody that has been pre-adsorbed on the surface of polystyrene microtiter wells.

The scientists found that the median ascitic fluid lactoferrin levels were significantly higher in patients with SBP than in those without SBP (112.7 ng/mL versus 0.6 ng/mL). The area under the receiver operator characteristic curve for the diagnosis of SBP was 0.898 with a sensitivity and specificity for a cut-off level of 51.4 ng/mL of 95.8 % and 74.4 %, respectively. Moreover, the incidence of HCC in the 78 patients without SBP was significantly higher in patients with high ascitic fluid lactoferrin levels (≥35 ng/mL) than in those with low ascitic fluid lactoferrin level (<35 ng/mL).

The authors concluded that ascitic fluid lactoferrin level can be a useful diagnostic tool to identify SBP in patients with ascites caused by cirrhosis and elevated ascitic fluid lactoferrin level in patients without SBP may be indicative of a developing hepatocellular carcinoma. The study was published on October 13, 2016, in the journal BMC Gastroenterology.

Related Links:
Gyeongsang National University Hospital
Bethyl Laboratories
Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.